PRESS RELEASE
Helsinki, Finland – Nanoform, an innovative medicine enabling nanotechnology company, has appointed Mike Rea as its Strategic Innovation Advisor. The role will involve working closely with Nanoform to maximise the value its proprietary nanonizationTM technology can deliver to pharmaceutical partners and patients globally.
Mike Rea will provide expert guidance on innovation development and technology positioning within the pharmaceutical ecosystem. He will utilize his extensive experience to strategically support the commercialization of Nanoform’s nanoparticle engineering technology.
Mike Rea is the CEO of IDEA Pharma, a company that develops path-to-market strategies for novel medicines. He has provided positioning and strategy for eight of the fifteen biggest pharmaceutical launches in the last three years and has been on The Medicine Maker Global Power List of the 100 most influential people in healthcare for 2017, 2018, and 2019. He notably created the Pharmaceutical Innovation Index, which is used to rank a pharma company’s ability to deliver innovation and identify the factors required for a successful launch. Mike Rea is also a Senior Fellow of FasterCures, a Milken Institute Center for accelerating medical research.
The appointment of a Strategic Innovation Advisor is a statement of Nanoform’s ambition to reduce attrition in the pharmaceutical pipeline. Nanoform’s technology will be applied to address difficult formulation challenges, such as poor solubility and bioavailability, and open up new avenues for novel drug delivery applications.
Edward Hæggström, CEO of Nanoform said: “We are delighted to be working with Mike on the positioning and strategy of our nanonizationTM platform. Our technology has the ability to significantly enhance the efficiency of pharmaceutical development, and with Mike on board, we will continue to support our pharma partners by increasing the number of their drugs that reach the market.”
Mike Rea said: “I have always been excited by connecting the different disciplines required for healthcare innovation and I was attracted to Nanoform’s multidisciplinary approach for advanced drug development. I look forward to helping Nanoform position its game-changing technology within the pharmaceutical marketplace.”
Notes to the Editor
For further information, images and interview opportunities with Nanoform, please contact:
Pranika Sivakumar at Notch Communications
Pranika.sivakumar@notchcommunications.co.uk
+44 (0) 161 457 7230
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization™ services. The company’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) technology produces nanonized “designed-for-purpose” API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique nanonization™ technology provides novel opportunities in diverse value enhancing drug delivery applications.
For more information please visit http://www.nanoform.fi/